Chinese researchers have identified specific spots in the genome of Chinese hamster ovary (CHO) cells where inserted genes yield substantially more antibodies, a finding that could speed up the development of biologic drugs. The work was carried out by teams at the Chinese Academy of Sciences and the University of Science and Technology of China.
CHO cells are the workhorse of antibody manufacturing across the biopharmaceutical industry, an sector worth more than $300 billion. Engineers typically insert the gene for a therapeutic antibody into random locations in the cell's chromosomes and then screen the resulting clones to find the most productive ones. That approach has a serious drawback. Random insertion can lead to uneven performance between clones, silenced genes and chromosomal rearrangements, and in some cases between 8 and 63 percent of clones prove unstable. Screening for good performers can take six to twelve months, slowing the path from laboratory to production.
To look for a better way, the researchers built a library of lentiviral vectors, let the cells grow for more than 60 generations, and then sorted out the top 1 percent of cells by fluorescence signal. They then used a new sequencing method, called NTTLA, to map 5,474 insertion sites across the CHO chromosomes. Most of the insertions, about 95 percent, fell in non-coding regions of DNA, which suggests that these stretches of the genome may be more hospitable to high expression than previously assumed.
Four of the newly identified sites delivered between 1.55 and 3.22 times the productivity of a commonly used reference site. The strongest clone produced 1.172 grams of antibody per liter in a three-liter fed-batch bioreactor. To test the candidate sites at scale, the team used an automated robotic platform, which allowed many validations to run in parallel.
The results remain preliminary. It is not yet clear whether these hotspots will stay stable over the long manufacturing campaigns used in commercial production, or whether they will perform the same way in other cell lines. Those questions will need to be answered before the approach can be applied widely in the industry.